Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Cash from Operations: 2017-2024

Historic Cash from Operations for BridgeBio Pharma (BBIO) over the last 8 years, with Dec 2024 value amounting to -$520.7 million.

  • BridgeBio Pharma's Cash from Operations rose 39.32% to -$109.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$584.8 million, marking a year-over-year decrease of 29.90%. This contributed to the annual value of -$520.7 million for FY2024, which is 1.33% up from last year.
  • BridgeBio Pharma's Cash from Operations amounted to -$520.7 million in FY2024, which was up 1.33% from -$527.7 million recorded in FY2023.
  • In the past 5 years, BridgeBio Pharma's Cash from Operations ranged from a high of -$399.7 million in FY2020 and a low of -$527.7 million during FY2023.
  • Over the past 3 years, BridgeBio Pharma's median Cash from Operations value was -$520.7 million (recorded in 2024), while the average stood at -$489.3 million.
  • Per our database at Business Quant, BridgeBio Pharma's Cash from Operations tumbled by 57.62% in 2020 and then rose by 15.75% in 2022.
  • BridgeBio Pharma's Cash from Operations (Yearly) stood at -$399.7 million in 2020, then fell by 24.57% to -$497.9 million in 2021, then grew by 15.75% to -$419.5 million in 2022, then fell by 25.80% to -$527.7 million in 2023, then increased by 1.33% to -$520.7 million in 2024.